The Latest Breaking News from NVO

Growth stock Novo Nordisk is showing strength after FDA approval of breakthrough oral drug for type 2 diabetes. Shares are in a base.

Prominent pharma player Novo Nordisk (NVO) posted solid revenue and earnings growth in fiscal 2022. The company’s long-term growth is expected to be spearheaded by its immensely popular GLP-1 drug Wegovy. Given the potential of its current portfolio of drugs and drugs under research, investing in this stock could be…

With slowing inflation, resilient economic growth, and a robust labor market aided by a slower rate hike by the Fed, fundamentally strong stocks Exxon Mobil (XOM), Novo Nordisk (NVO), and Bridgestone (BRDCY) seem to be good investments now. Continue reading….

GSK stock and NVO stock rose Wednesday, though both beat forecasts. Novartis stock skidded on lighter-than-expected sales.

Although inflation has cooled down over the past few months, the Fed intends to keep raising interest rates until inflation falls to its desired level. This is expected to push the economy into a recession. Investors looking to stabilize their portfolios against potential market volatility might look to add large-cap…

The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday.

The healthcare industry is poised to grow significantly in the coming years. Moreover, as healthcare stocks tend to perform relatively well despite macro uncertainties due to inelastic demand for their products and services, high-flying pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Merck & Co (MRK) might be ideal investments…

Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

The stock market has witnessed significant volatility amid the record high inflation and the Fed’s hawkish stance on it. Investors have been banking on healthcare stocks as they tend to hold up relatively well in such turbulent times. We think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer…

The Fed’s hawkish stance on inflation, along with other macroeconomic issues, has created substantial market volatility. However, it might be better to stay invested to reap long-term returns. To that end, fundamentally sound stocks Novo Nordisk (NVO), Centene (CNC), McKesson (MCK), Universal Logistics (ULH), and Sisecam Resources (SIRE) might be…